All Stories

AstraZeneca pays $160M for Fibrogen's China unit, regional rights to roxadustat

AstraZeneca is paying $160 million for Fibrogen’s Chinese business, giving the U.K.-based Big Pharma the regional rights to oral anemia drug roxadustat.

Feb 20, 2025 - 14:53
 0
AstraZeneca pays $160M for Fibrogen's China unit, regional rights to roxadustat
AstraZeneca is paying $160 million for Fibrogen’s Chinese business, giving the U.K.-based Big Pharma the regional rights to oral anemia drug roxadustat.
Read More

Tags:

Previous Article

Tesla 'Violated' Workplace Safety Before Worker Death

Next Article

Orphan designation: [4-(Methyl-1H-pyrazol-4-yl)-benzyl]-(6[7-(3-pyrrolidin-1-yl-...

Related Posts

Fierce Pharma Asia—Novo Nordisk's fraud accusation; AstraZeneca's China deal; Ono's FDA nod

Fierce Pharma Asia—Novo Nordisk's fraud accusation; Ast...

Feb 21, 2025  0

Argenx puts marketing muscle behind CIDP launch with Vyvgart Hytrulo TV campaign

Argenx puts marketing muscle behind CIDP launch with Vy...

Feb 18, 2025  0

Regulatory tracker: Bristol Myers snags dual cancer endorsements in EU

Regulatory tracker: Bristol Myers snags dual cancer end...

Feb 10, 2025  0